Trial Profile

A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2023 Updated results (n=48) assessing efficacy and toxicity of the Ibrutinib Obinutuzumab plus venetoclax combination in both R/R and untreated MCL patients presented at the 28th Congress of the European Haematology Association
13 Dec 2022 Results by deriving tumor DNA from patients enrolled in the OAsIs trial, for assessing in vivo resistance to Ibrutinib/Venetoclax , presented at the 64th American Society of Hematology Annual Meeting and Exposition
20 Nov 2020 To prevent tumor lysis syndrome (TLS), the protocol was amended to include an additional venetoclax ramp up cycle called cycle 1-b

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com